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MaBACKGROUND Up to 65% of patients with ST-segment elevation myocardial infarction (STEMI) have multivessel coro-
nary artery disease (MVCAD). Long-term health status of STEMI patients after multivessel revascularization is unknown.
OBJECTIVES This study investigated the relationship between multivessel revascularization and health status out-
comes (symptoms and quality of life [QoL]) in STEMI patients with MVCAD.
METHODS Using a U.S. myocardial infarction registry and the Seattle Angina Questionnaire (SAQ), we determined the
health status of patients with STEMI and MVCAD at the time of STEMI and 1 year later. We assessed the association of
multivessel revascularization during index hospitalization with 1-year health status using multivariable linear regression
analysis, and also examined demographic, clinical, and angiographic factors associated with multivessel revascularization.
RESULTS Among 664 STEMI patients with MVCAD, 251 (38%) underwent multivessel revascularization. Most revas-
cularizations were staged during the index hospitalization (64.1%), and 8.0% were staged after discharge, with 27.9%
performed during primary percutaneous coronary intervention. Multivessel revascularization was associated with age and
more diseased vessels. At 1 year, multivessel revascularization was independently associated with improved symptoms
(4.5 points higher SAQ angina frequency score; 95% conﬁdence interval [CI]: 1.0 to 7.9) and QoL (6.6 points higher SAQ
QoL score; 95% CI: 2.7 to 10.6). One-year mortality was not different between those who did and did not undergo
multivessel revascularization (3.6% vs. 3.4%; log-rank test p ¼ 0.88).
CONCLUSIONS Multivessel revascularization improved angina and QoL in STEMI patients with MVCAD.
Patient-centered outcomes should be considered in future trials of multivessel revascularization.
(J Am Coll Cardiol 2015;66:2104–13) © 2015 by the American College of Cardiology Foundation.m the *Cardiovascular Outcomes Research, Saint Luke’s Mid America Heart Institute, Kansas City, Missouri; yUniversity of
ssouriKansas City, Kansas City, Missouri; zDepartment of Cardiology, Busan Paik Hospital, Inje University College of Medi-
e, Busan, Republic of Korea; xDivision of Cardiology, Kaiser Permanente Medical Center, San Francisco, California;
ardiovascular Division, Washington University School of Medicine, St. Louis, Missouri; and the {Barnes-Jewish Hospital, St.
uis, Missouri. The TRIUMPH study was funded by a grant from the NHLBI (P50 HL 077113) and CV Outcomes (Kansas City,
ssouri). Drs. Shaﬁq, Grodzinsky, and Fendler received support from the National Heart, Lung, and Blood Institute of the Na-
nal Institutes of Health under Award Number T32HL110837. Dr. Amin is funded via a comparative effectiveness research KM1
eer development award from the Clinical and Translational Science Award (CTSA) program of the National Center for
vancing Translational Sciences of the National Institutes of Health, Grant Numbers UL1TR000448, KL2TR000450,
1TR000449; and the National Cancer Institute of the National Institutes of Health, Grant Number 1KM1CA156708-01; and is a
nsultant with Teruno, The Medicines Company, and AstraZeneca. Dr. Jang was supported by the National Research Foundation
Korea (NRF) grant funded by the Korean government (MSIP) (No. R13-2007-023-00000-0). Dr. Spertus owns the copyright to the
attle Angina Questionnaire, KCCQ, and PAQ; and has equity in Health Outcome Sciences. Dr. Grantham has received grants,
noraria, speaking fees, and travel reimbursement from Medtronic, Boston Scientiﬁc, Abbott Vascular, and ASAHI Intecc; is a
areholder of and has intellectual property with Insysiv, LLC. All other authors have reported that they have no relationships
evant to the contents of this paper to disclose. Timothy D. Henry, MD, served as Guest Editor for this paper.
nuscript received August 1, 2015; revised manuscript received August 21, 2015, accepted August 25, 2015.
AB BR E V I A T I O N S
AND ACRONYM S
AF = angina frequency
AMI = acute myocardial
infarction
CABG = coronary artery bypass
grafting
LAD = left anterior descending
MRR = median rate ratio
MVCAD = multivessel
coronary artery disease
PCI = percutaneous coronary
intervention
QoL = quality of life
SAQ = Seattle Angina
Questionnaire
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2105A mong ST-segment elevation myocardial in-farction (STEMI) patients, 40% to 65% have1 or more signiﬁcant coronary stenoses in
addition to their culprit vessels (1). When and how
to treat these nonculprit vessels is controversial (2).
Options include revascularization at the time of pri-
mary percutaneous coronary intervention (PCI), later
during the acute myocardial infarction (AMI) hospi-
talization, or medical therapy with or without subse-
quent elective revascularization after discharge.
Current guidelines recommend that only the culprit
vessel be treated during index PCI in the absence of
hemodynamic instability after opening the culprit ar-
tery (3,4), with staged procedures being considered in
case of symptoms or ischemia within days to weeks
after primary PCI (5).SEE PAGE 2114
STEMI = ST-segment elevation
myocardial infarctionRecently, several observational studies have been
published with conﬂicting results about the beneﬁts
of nonculprit PCI (6–8). These observational studies
have been supplemented with randomized trials,
including PRAMI (Preventive Angioplasty in Acute
Myocardial Infarction) (9) and CvLPRIT (Complete
versus Lesion only Primary-PCI Trial) (10), that have
reported better composite outcomes in STEMI pa-
tients treated with complete revascularization at the
time of primary PCI or during the index hospitaliza-
tion. Importantly, these studies did not examine
patient-reported outcomes, and there have been no
data reported on the long-term health status out-
comes of culprit-only or multivessel revasculariza-
tion. This is particularly important as reduced angina
and improved quality of life (QoL) could be important
potential beneﬁts of treating nonculprit ﬂow-limiting
lesions, similar to the results of studies in population
of patients with stable coronary artery disease (11,12).
To deﬁne the potential patient-centered beneﬁts of
complete revascularization, we sought to describe the
patterns of treating noninfarct vessels, patient char-
acteristics associated with multivessel revasculariza-
tion, variation in practice across hospitals, and the
independent association of multivessel revasculari-
zation with 1-year health-related QoL and mortality.
METHODS
STUDY PROTOCOL AND POPULATION. The TRIUMPH
(Translational Research Investigating Underlying
Disparities in Acute Myocardial Infarction Patients’
Health Status) study is a prospective, multicenter
cohort study of 4,340 AMI patients enrolled at 24 U.S.
centers between April 2005 and December 2008.
Patients were eligible for inclusion if they were$18 years of age and had an AMI, and elevated
biomarkers with either electrocardiographic
changes or symptoms consistent with the
diagnosis (13). TRIUMPH was approved by the
institutional research board at each partici-
pating site and written informed consent was
obtained from all participants.
From the overall TRIUMPH cohort, we ﬁrst
identiﬁed patients with STEMI and multi-
vessel coronary artery disease (MVCAD),
which was deﬁned as having at least 2 of 3
epicardial vessels with a stenosis $70% or left
main stenosis $50%. Given the goal of
examining practice patterns and long-term
outcomes in STEMI patients with MVCAD,
we excluded those with nonST-segment
elevation myocardial infarction (NSTEMI),
prior coronary artery bypass grafting (CABG),
and those who died during hospitalization.
DEFINITION OF MULTIVESSEL REVASCULARIZATION.
Multivessel revascularization was deﬁned as revascu-
larization of all major coronary stenoses during the
index hospitalization or within 6 weeks of discharge
with either PCI or CABG, such that there was no resid-
ual stenosis $70% in any major epicardial coronary
artery. This deﬁnition included simultaneous non-
culprit PCI during the index primary PCI, staged
revascularizations during the index admission, and
elective procedures performed within 6 weeks of dis-
charge. For patients undergoing CABG during the index
hospitalization or within 6 weeks of discharge, we
assumed that complete revascularization had been
performed. Conversely, we deﬁned culprit-only revas-
cularization as PCI to the culprit vessel only during
the index hospitalization or multivessel PCI with re-
sidual untreated or unsuccessfully treated noninfarct
artery stenoses $70% after the index primary PCI.
OUTCOMES. Disease-speciﬁc health status was pro-
spectively assessed using the Seattle Angina Ques-
tionnaire (SAQ) at the time of patients’ index
hospitalizations and at 1-year follow-up. The SAQ is a
19-item patient-reported health status instrument
with a recall period of 4 weeks that quantiﬁes 5 clini-
cally relevant domains of coronary disease, including
angina frequency (SAQ AF) and quality of life (SAQ
QoL). Scores in these domains range from 0 to 100,
with higher scores indicating fewer symptoms and
better QoL (14). The SAQ has been demonstrated to
be valid, reliable, and sensitive to clinical changes
(14–17) and is also associated with subsequent reho-
spitalization and health care costs (18–20). As a sec-
ondary outcome of interest, we assessed all-cause
mortality for a period of 1 year after the index
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2106admission using a combination of phone follow-up
and the Social Security death master index. We also
examined the rates of severe angina (deﬁned as hav-
ing more than 3 episodes of angina per week as
deﬁned by a SAQ AF score of #40), myocardial
infarction, and repeat revascularization procedures
(PCI or CABG) during the year after patients’ initial
AMI.
STATISTICAL ANALYSIS. Baseline clinical and de-
mographic characteristics were compared between
those with multivessel versus culprit-only revascu-
larization using the Student t test or Mann-Whitney U
tests for continuous variables and chi-square or
Fisher exact test for categorical variables, as appro-
priate. To identify factors associated with multivessel
revascularization, we used a multivariable, hierar-
chical (adjusting for site as a random effect) modiﬁed
Poisson regression model with robust variance esti-
mation (21). Factors included in the model were
selected a priori, on the basis of published data re-
view and clinical judgment, and included age; sex;
race; history of atrial ﬁbrillation, diabetes mellitus
and congestive heart failure; left ventricular systolic
function; number of diseased vessels; nonleft
anterior descending (LAD) artery as the culprit artery;
development of in-hospital heart failure after the
primary PCI; baseline creatinine; baseline hemoglo-
bin; short form-12 physical component scale score at
baseline; presence of angina before admission;
ﬁnancial status; and avoidance of health care services
due to cost. Variation in the practice of multivessel
revascularization across the study sites was assessed
using the median rate ratio (MRR) (22,23).1 Study Inclusion and Exclusion Criteria
patients enrolled in TRIUMPH
3,803 Patients
1,074 Patients
1,585 Patients
1,070 Patients
537 Pts excluded (prior CABG)
2,218 Pts Excluded (not undergoing
angiography, or no MVCAD)
511 Pts Excluded (no PCI during index
AMI hospitalization)
4 Pts Excluded (died in–hospital)
406 Pts Excluded (NSTEMI)
STEMI Patients with MVCAD
Analytic Cohort
coronary artery bypass grafting; MVCAD ¼ multivessel coronary
isease; NSTEMI ¼ non-ST-segment elevation myocardial infarction;
ercutaneous coronary intervention; STEMI ¼ ST-segment elevation
ial infarction; TRIUMPH ¼ Translational Research Investigating
ing disparities in acute Myocardial infarction Patients’ Health Status.The association of multivessel revascularization
with 1-year health status outcomes was evaluated
using hierarchical (adjusting for site as a random ef-
fect) multivariable linear regression models for each
health status outcome (SAQ AF and SAQ QoL). Cova-
riates for adjustment were selected a priori, on the
basis of published data review and clinical judgment,
and included baseline health status scores, age, sex,
race, history of smoking, number of diseased vessels,
non-LAD as the culprit artery, in-hospital heart fail-
ure after the primary PCI, baseline creatinine, base-
line hemoglobin, and self-reported avoidance of
health care services due to cost. Because these
models included baseline health status, the regres-
sion coefﬁcient for the “multivessel” versus culprit-
only artery revascularization variable represented
the difference between these 2 groups in the
improvement of the health status scores from base-
line to 1 year, adjusted for all covariates.
The associations of multivessel revasculariza-
tion with 1-year mortality, myocardial infarction,
and repeat revascularization were assessed using
Kaplan-Meier survival analysis and the log-rank test.
Finally, we performed a sensitivity analysis excluding
patients undergoing CABG to determine whether our
results were comparable in the PCI-only patients. All
statistical analyses were conducted using SAS version
9.3 (SAS Institute Inc., Cary, North Carolina).
MISSING DATA. Two hundred twenty-four (33.7%) of
the 664 patients did not have a follow-up SAQ score at
1 year. Outcomes data were missing equally in the 2
groups. Baseline characteristics were compared be-
tween those with versus without missing data and
we sought to minimize the effect of selection bias
(due to loss-to-follow-up) by constructing a non-
parsimonious, multivariable logistic regression model
to determine the probability of having missing data.
We then weighted each of the observed patients by
the inverse probability of the likelihood to having
missing data (24) so that we preferentially weighted
the experience of those most like the patients who
were missing follow-up assessments.
RESULTS
PATIENT POPULATION. Of the 4,340 patients
enrolled in TRIUMPH, 537 patients with a history
of prior CABG were excluded. We also excluded
2,218 patients with single vessel coronary disease
or who did not undergo diagnostic angiography.
We further excluded 406 NSTEMI patients and 4
patients who died before discharge, making our
ﬁnal analytic cohort 664 patients with STEMI and
MVCAD (Figure 1). Among these, 413 (62%) underwent
TABLE 1 Baseline Demographic and Clinical Characteristics by Categories of
Multivessel Versus Culprit-Only Revascularization
Multivessel
(n ¼ 251)
Culprit-Only
(n ¼ 413) p Value
Socio-demographic variables
Age, yrs 56.4  10.0 58.7  12.1 0.012
Caucasian 197 (79.4) 299 (72.7) 0.053
Female 62 (24.7) 108 (26.2) 0.678
Insurance: none/self-pay 58 (23.7) 92 (22.9) 0.830
Medical history and clinical variables
Diabetes 59 (23.5) 106 (25.7) 0.532
Hypertension 144 (57.4) 242 (58.6) 0.756
Dyslipidemia 115 (45.8) 190 (46.0) 0.962
Prior PCI 29 (11.6) 78 (18.9) 0.012
Chronic heart failure 5 (2.0) 8 (1.9) 1.000
Peripheral vascular disease 5 (2.0) 16 (3.9) 0.179
Smoking 156 (62.2) 252 (61.0) 0.770
In-hospital heart failure 15 (6.0) 15 (3.6) 0.158
LV dysfunction, EF <40% 43 (18.4) 79 (21.0) 0.438
Peak troponin I/T, ng/dl 23.8 13.7 <0.001
Hemoglobin, g/dl: initial 15.0 14.7 0.035
Systolic BP, mm Hg: initial 142.0 140.0 0.443
Angiographic and procedural characteristics
Number of diseased vessels 2.5  0.7 2.4  0.6 <0.001
Number of vessels treated 1.9  0.6 1.0  0.0 <0.001
Distribution of culprit vessels <0.001
Left main coronary artery 1 (0.4) 3 (0.7)
Proximal left anterior descending artery 45 (17.9) 31 (7.5)
Mid to distal left anterior descending artery 42 (16.7) 116 (28.1)
Left circumﬂex artery 23 (9.2) 50 (12.1)
Right coronary artery 109 (43.4) 181 (43.8)
Other 1 (0.4) 3 (0.7)
Unknown 30 (12.0) 29 (7.0)
Left anterior descending artery culprit 87 (34.7) 147 (35.6) 0.807
Distribution of nonculprit vessels
Left main coronary artery 10 (4.0) 18 (4.4) 0.815
Proximal left anterior descending artery 25 (10.0) 12 (2.9) <0.001
Mid to distal left anterior descending artery 119 (47.4) 169 (40.9) 0.101
Left circumﬂex artery 112 (44.6) 206 (49.9) 0.188
Right coronary artery 74 (29.5) 134 (32.4) 0.424
Other 26 (10.4) 28 (6.8) 0.101
Number of bare-metal stents 0.8  1.2 0.7  0.9 0.556
Number of drug-eluting stents 1.6  1.6 0.7  0.9 <0.001
In-hospital revascularization <0.001
PCI 223 (88.8) 413 (100.0)
CABG 28 (11.2) 0
Values are mean  SD, n (%), or median.
BP ¼ blood pressure; CABG ¼ coronary artery bypass grafting; EF ¼ ejection fraction; LV ¼ left ventricular;
PCI ¼ percutaneous coronary intervention.
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2107culprit-only PCI and 251 (38%) underwent multivessel
revascularization. Of those undergoing complete re-
vascularization, most were staged during index hos-
pitalization (n ¼ 161, 64.1%), 20 (8.0%) were
performed shortly after discharge, and 70 (27.9%)
were treated during their primary PCI. The mode of
multivessel revascularization was percutaneous in
88% of patients. The baseline characteristics of those
who underwent multivessel versus culprit-only revas-
cularization are displayed in Table 1. Patients under-
going multivessel revascularization were younger,
had less history of prior PCI, had higher peak tropo-
nin and hemoglobin levels, received more drug-
eluting stents, had a greater number of diseased
vessels, and were more likely to have proximal LAD
artery involvement of the nonculprit artery.
FACTORS ASSOCIATED WITH MULTIVESSEL REVAS-
CULARIZATION. The factors independently associated
with multivessel revascularization were the number
of diseased vessels (relative risk: 1.31 per additional
vessel; 95% conﬁdence interval [CI]: 1.17 to 1.46) and
age (Figure 2). Age displayed a nonlinear, inverse
J-shaped association with multivessel revasculariza-
tion. Whereas older patients were less likely to
receive multivessel revascularization, as compared
with patients around age 50 years, the youngest
patients also showed a trend towards less multivessel
revascularization, which was not statistically signiﬁ-
cant (Online Figure 1).
The average rate of multivessel revascularization
across the population was 38%; however, we ob-
served marked variation across study sites, ranging
from 0% to >70% (Figure 3). The MRR, a statistical
measure of variation, was 1.30, suggesting an average
30% greater likelihood of undergoing multivessel
revascularization for patients with identical charac-
teristics who present at one randomly selected TRI-
UMPH site as compared with another.
MULTIVESSEL VERSUS CULPRIT-ONLY REVASCULARI-
ZATION AND HEALTH STATUS OUTCOMES. Among the
664 eligible patients, 224 (33.7%) did not have a
follow-up SAQ score at 1 year. These data were
missing equally in the 2 groups and were addressed
with inverse probability weighting to preferentially
weight the experience of patients most like those
missing follow-up data. There were improvements in
unadjusted health status from baseline to 1 year in
both groups (Table 2), although these improvements
were greater in the multivessel revascularization
group. On average, the unadjusted SAQ AF score in
the multivessel group was 4.09 points higher than the
culprit-only group (95% CI: 0.56 to 7.63) (Figure 4A).
The proportion of patients reporting symptoms ofsevere angina (i.e., more than 3 angina episodes per
week) at 1 year was not signiﬁcantly different
between the 2 groups (4.4% vs. 6.3%; p ¼ 0.34)
(Table 2). The unadjusted SAQ QoL score was also
signiﬁcantly greater in the multivessel group by 5.18
points (95% CI: 1.17 to 9.19). After multivariable
regression with inverse probability weighting to
adjust for baseline patient characteristics, there was a
FIGURE 2 Independent Correlates of Multivessel Revascularization
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1.08 (0.88, 1.34)
1.04 (0.84, 1.29)
1.31 (1.17, 1.46)
1.02 (0.77, 1.37)
1.33 (0.79, 2.23)
1.44 (0.95, 2.19)
0.63 (0.29, 1.35)
0.91 (0.67, 1.25)
0.90 (0.65, 1.26)
0.78 (0.39, 1.54)
1.08 (0.82, 1.42)
0.98 (0.95, 1.02)
0.90 (0.77, 1.05)
1.30 (1.18, 1.97)
Age
– 40 vs. 50
– 60 vs. 50
– 70 vs. 50
– 80 vs. 50
Female
Caucasian
Avoid care due to costs
Diseased vessels (per 1 increment)
Non–LAD culprit vessel
History of CHF
In–hospital heart failure
History of atrial fibrillation
History of diabetes mellitus
LV systolic dysfunction (moderate or severe)
Initial creatinine (per 5 units increment)
Initial hemoglobin (per 5 units increment)
SF–12 PCS (per 5 units increment)
Angina at baseline
Hospital site (median rate ratio)
X-axis shows the rate ratio for undergoing multivessel revascularization. Age and number
of diseased vessels were independently associated with multivessel revascularization.
CHF¼ chronic heart failure; CR¼ complete revascularization; LAD¼ left anterior descending;
LV¼ left ventricular; SF-12 PCS ¼ short form-12 physical component scale score.
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2108signiﬁcant difference in the degree of improvement
from baseline to 1 year between the groups of patients
who underwent complete, as compared with culprit-
only, revascularization. The SAQ AF score was 4.45
points (95% CI: 0.99 to 7.91) higher and the SAQ QoL
score was 6.63 points (95% CI: 2.67 to 10.59)
(Figure 4A) higher with multivessel versus culprit-
only revascularization. The interaction of the timing
of complete revascularization (at the time of primary
PCI, later in the hospital stay or shortly after
discharge) was not signiﬁcant (p ¼ 0.64 and p ¼ 0.69
for SAQ AF and SAQ QoL, respectively).
MULTIVESSEL VERSUS CULPRIT-ONLY REVASCU-
LARIZATION AND CLINICAL OUTCOMES. There was
no difference in 1-year mortality between those who
did and did not undergo multivessel revasculariza-
tion (3.6% vs. 3.4%; log-rank test p ¼ 0.88) (Table 2,
Online Figure 2). A total of 32 patients (9.1%) in the
culprit-only group and 17 patients (7.5%) in the
multivessel revascularization group underwent fur-
ther revascularization during 12 months (log-rank test
p ¼ 0.50).
SENSITIVITY ANALYSES. When these analyses were
repeated in the PCI-only cohort, patients who under-
went multivessel PCI had signiﬁcant improvementsin health status as compared with culprit-only PCI.
The multivariable-adjusted difference in SAQ AF
scores was 5.34 points (95% CI: 1.77 to 8.92) and in SAQ
QoL scores it was 7.78 points (95% CI: 3.79 to 11.77)
(Figure 4B).
DISCUSSION
To evaluate the health status differences between
multivessel and culprit-only revascularization in
STEMI patients, we analyzed a multicenter study of
contemporary revascularization practice in the
United States. We found that multivessel revasculari-
zation was performed in 38% of STEMI patients with
MVCAD and that there was modest variation across
hospitals. Patient characteristics independently
associated with multivessel revascularization in-
cluded age and a higher number of diseased vessels.
Finally, multivessel revascularization was associated
with improvements in both angina and QoL, but
not mortality or repeat revascularization procedures,
1 year after discharge (Central Illustration). To our
knowledge, this is the ﬁrst study to evaluate patients’
perception of their symptoms and QoL after complete
versus culprit-only revascularization in patients with
STEMI and MVCAD and these data extend recent in-
sights from clinical trials of a potential clinical beneﬁt
from complete revascularization by also suggesting an
improvement in patients’ 1-year health status.
Several recent studies of different revasculariza-
tion strategies in STEMI patients and MVCAD have
been performed (2,25,26), with 2 randomized clinical
trials showing better clinical outcomes with com-
plete revascularization (9,10). The PRAMI study
compared multivessel (complete) PCI versus culprit-
only PCI at time of primary PCI in 465 STEMI pa-
tients with MVCAD and found that multivessel PCI
decreased the incidence of the primary composite
endpoint of cardiac death, nonfatal myocardial
infarction, or refractory angina (hazard ratio [HR]:
0.35; 95% CI: 0.21 to 0.58; p < 0.001) (9). They also
reported signiﬁcantly lower refractory angina (HR:
0.35; 95% CI: 0.18 to 0.69; p ¼ 0.002) and repeat
revascularization (HR: 0.30; 95% CI: 0.17 to 0.56;
p < 0.001) in the multivessel revascularization group.
Another recent randomized trial, CvLPRIT (10),
compared a strategy of complete in-hospital revas-
cularization with culprit-only PCI and ischemia-
based subsequent revascularization in 296 STEMI
patients with MVCAD at time of primary PCI. They
found that complete revascularization, including
staged in-hospital procedure before discharge, was
associated with a lower incidence of death, myocar-
dial infarction, heart failure, or ischemia-driven
FIGURE 3 Hospital Variation in the Rate of Multivessel Revascularization
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X-axis shows individual hospital sites arranged in increasing order of their rate of multivessel revascularization. Median rate ratio, a statistical
measure of variation, was 1.30, suggesting an average 30% higher likelihood of undergoing multivessel revascularization for patients with
identical characteristics who present to 2 randomly selected TRIUMPH (Translational Research Investigating Underlying disparities in acute
Myocardial infarction Patients’ Health Status) sites.
TABLE 2 Baseline and 1-Year Health Status Outcomes and Clinical Outcomes
Multivessel
(n ¼ 251)
Culprit-Only
(n ¼ 413) p Value
Health status measures
SAQ AF score (baseline) 89.6  17.1 89.2  16.8 0.77
SAQ AF score (1 yr) 94.8  14.2 92.8  17.4 0.20
Mean changes in SAQ AF 5.2  22.4 3.2  20.8 0.34
SAQ QoL score (baseline) 62.3  20.9 68.5  22.9 <0.001
SAQ QoL score (1 yr) 85.0  18.3 81.5  20.7 0.07
Mean changes in SAQ QoL 22.3  24.9 12.7  26.5 <0.001
Clinical outcomes at 1 yr
Mortality 8 (3.6) 14 (3.4) 0.88
Recurrent MI 7 (3.5) 4 (1.4) 0.12
Repeat revascularization 17 (7.5) 32 (9.1) 0.50
Severe angina 10 (4.4) 22 (6.3) 0.34
Values are mean  SD or n (%).
AF ¼ angina frequency; MI ¼ myocardial infarction; QoL ¼ quality of life; SAQ ¼ Seattle Angina Questionnaire.
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2109revascularization at 12 months (10). Our ﬁndings
extend with these trials by ﬁnding less angina and
better disease-speciﬁc QoL at 1 year, although we
were not adequately powered to detect a difference
in mortality or subsequent revascularization.
Our study also revealed interesting patterns in
the practice of selecting patients with MVCAD for
multivessel revascularization during a STEMI hospi-
talization. Among diverse care settings throughout
the United States, we found that the very old and very
young patients were less likely to undergo multi-
vessel revascularization. Similarly, those with a
higher number of diseased vessels were more likely to
undergo complete revascularization during their
hospitalization, rather than at the time of primary
reperfusion. Several other factors (e.g., history of
prior PCI, troponin level, distribution of culprit ves-
sels) that were signiﬁcantly different between pa-
tients receiving different revascularization strategies
were not independently correlated with multivessel
revascularization within 6 weeks of an AMI. Unmea-
sured confounding or selection bias may have inﬂu-
enced our ﬁndings because we did not query the
clinicians about why complete or culprit-only revas-
cularization was performed. Our ﬁndings thusemphasize the need for future randomized trials to
compare these 2 revascularization strategies and to
explicitly measure the effects of treatment strategy
on QoL, an outcome of critical importance to patients.
However, the majority of multivessel revas-
cularizations in our study seemed to be driven largely
by clinical factors, such as worsening clinical status
FIGURE 4 Association of Revascularization Strategies With Health Status Outcomes
-10 -5 0 5 10 -10 -5 0 5 10
Decline in score Improvement in score Decline in score Improvement in score
4.09 (0.56, 7.63)
4.45 (0.99, 7.91)
5.18 (1.17, 9.19)
6.63 (2.67, 10.59)
5.01 (1.34, 8.67)
5.34 (1.77, 8.92)
6.78 (2.77, 10.79)
7.78 (3.79, 11.77)
SAQ AF
Unadjusted
Adjusted
SAQ QoL
Unadjusted
Adjusted
Entire cohort (PCI + CABG) PCI only cohortA B
The point estimates represent the difference in improvement (from baseline to 1 year) in SAQ AF and SAQ QoL scores and the numbers in
parentheses represent the 95% CI for the entire cohort (A) and the PCI only cohort (B). Estimates (with 95% CI) to the right of the vertical
dotted line represent improvement in health status, whereas those to the left of the vertical dotted line represent decrement in health status.
AF ¼ angina frequency; QoL ¼ quality of life; SAQ ¼ Seattle Angina Questionnaire; other abbreviations as in Figure 1.
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2110and anatomic considerations, rather than by pre-
senting sites or physician factors. In fact, the MRR
showed only modest variability with only an average
30% variation in the likelihood of receiving multi-
vessel revascularization for a given patient present-
ing to 1 hospital in our cohort versus another. These
variations in care may stem from confusion in the
existing published data surrounding the optimal
treatment strategy for STEMI patients with MVCAD.
Some of this variation might be attributable to the
difﬁculty in interpreting previous studies with
different timing and deﬁnition of staged and com-
plete revascularization while examining the out-
comes of complete revascularization (9,10,25–33) and
emphasizes the opportunity to improve the consis-
tency and quality of care for STEMI patients with
MVCAD. Studies excluding staged procedure from
either complete or culprit-only groups reported better
outcomes in the culprit-only arm (34,35). Conversely,
studies considering staged PCI, including staged
in-hospital PCI procedures as a complete revascular-
ization strategy, reported better outcomes with
complete revascularization (9,33,36). Congruent with
these ﬁndings, our deﬁnition of staged procedure
included all settings in which multivessel revascu-
larization was accomplished either in the hospital or
shortly thereafter. Importantly, we found no signiﬁ-
cant interaction between different strategies of per-
forming multivessel revascularization on outcomes,
suggesting similar outcomes with any of the 3
approaches to complete revascularization.Current guidelines do not recommend revasculari-
zation of the noninfarct artery unless indicated by
hemodynamic instability or persistent ischemia after
PCI of the supposed culprit lesion (3,4) and the clini-
cians following these patients in the outpatient
setting may not recommend intervention for mildly
symptomatic STEMI patients. This is supported by our
ﬁndings that there was not a signiﬁcantly higher
prevalence of severe angina in the culprit-only group.
However, patients with multivessel revascularization
had a statistically and clinically signiﬁcant 7-point
greater improvement in SAQ QoL as compared with
those undergoing culprit-only PCI, even after adjust-
ing for baseline health status and other factors, and a
slightly smaller, 4.5-point mean improvement in SAQ
AF scores that were larger than those observed in the
COURAGE (Clinical Outcomes Utilizing Revasculari-
zation and Aggressive Drug Evaluation) trial (37). One
may therefore wonder why patients who have resid-
ual angina in the year after AMI might not receive
more aggressive antianginal therapy or undergo
revascularization of their untreated stenosis.
Although our study cannot provide an explanation
for this, there is known to be variability in the quality
of follow-up care that may preclude more aggressive
treatment of patients’ angina and, given our ﬁndings
of better angina control and disease-speciﬁc QoL, we
believe that more complete revascularization at the
time of a STEMI might be warranted (38). To deﬁnitely
prove this, however, randomized trials that system-
atically measure patients’ health status are needed.
CENTRAL ILLUSTRATION Health Status Outcomes After Multivessel Revascularization
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          TIMING OF
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Timing of revascularization and outcomes. SAQ ¼ Seattle Angina Questionnaire; STEMI ¼ ST-segment elevation myocardial infarction.
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2111STUDY LIMITATIONS. Our study should be inter-
preted in the context of several potential limitations.
First, in light of the observational nature of our data,
it is not possible to establish a causal relationship
between multivessel revascularization and improved
QoL at 1 year. Patients in our study were likely aware
of whether their residual coronary stenoses were
ﬁxed or not and this may have inﬂuenced their per-
ceptions of recurrent chest pain or perceived QoL.
Although these data suggest that health-related QoL
is improved with multivessel revascularization in
STEMI patients with MVCAD, unmeasured con-
founding or selection bias cannot be excluded and
may have inﬂuenced our ﬁndings. Second, we didnot query the clinicians as to why complete or
culprit-only revascularization was performed and
there may have been prognostically important con-
siderations that were not included in our risk-
adjusted models. A randomized trial would be
needed to remove this confounding, although it
is possible that patients in whom the physicians
believed complete revascularization would be needed
would not enroll such patients.
A third consideration in the interpretation of our
ﬁndings is that one-third of patients were missing
SAQ data at 1 year that may have introduced a
selection bias, although the rates at which these
data were missing did not differ between those
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Mul-
tivessel revascularization at time of primary PCI or
during index hospitalization in patients with STEMI is
associated with better symptom status and quality of
life 1 year later.
TRANSLATIONAL OUTLOOK: Additional studies
are needed to guide selection of patients with acute
STEMI for immediate versus staged multivessel PCI.
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2112with culprit-only and multivessel revascularization.
A fourth concern is that an angiographic core labo-
ratory was not used to assess the severity of CAD
and angiographic data were obtained by chart
abstraction of the dictated reports. Any mis-
classiﬁcations, however, might be expected to bias
our study results toward the null. In addition, our
secondary analysis of mortality outcomes had
limited power to detect any differences in survival.
Given the importance of survival, adequately
powered randomized clinical trials will be needed
to better deﬁne the impact of complete revasculari-
zation on subsequent mortality. Finally, we
excluded patients who did not survive to hospital
discharge, and, as such, the observed beneﬁts of
multivessel revascularization cannot be extrapolated
to extremely sick patients.
CONCLUSIONS
In a large multicenter AMI registry, we found that
multivessel revascularization in the setting of STEMI
was common, varied by both patient characteristics
and the treating hospital, and was strongly associated
with a clinically signiﬁcant improvement in both
angina and QoL 1 year after treatment. Future studiesof the potential beneﬁts and harms of multivessel
revascularization in STEMI patients should include
both symptoms and health-related QoL outcomes so
that more complete insights into the beneﬁts of
multivessel, as compared with culprit-only, revascu-
larization can be assessed.
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